News • Hard to treat cancers
KRAS “degrader” could lead to treatment for millions of cancer patients
A newfound molecule, called ACBI3, could potentially lead to new therapies against hard-to-treat cancers, improving outcomes for all patients with cancers caused by KRAS mutations.